Menjembatani Kesenjangan dalam Manajemen Dislipidemia di Indonesia Melalui Strategi ACS Europath
Analisis
DOI:
https://doi.org/10.55175/cdk.v52i4.1384Kata Kunci:
Sindrom koroner akut, dislipidemia, LDL, terapi penurun lipidAbstrak
Dislipidemia adalah masalah kesehatan masyarakat yang signifikan secara global, khususnya di Indonesia. Pedoman dislipidemia saat ini menyatakan bahwa tata laksana harus dilakukan dengan menggabungkan intervensi gaya hidup dan pengobatan farmakologi. Pengobatan dengan agen penurun lipid harus dimulai lebih awal untuk manfaat prognostik yang lebih baik. Proyek ACS Europath IV menekankan pentingnya intensifikasi dini terapi penurun lipid untuk mengurangi risiko kejadian kardiovaskular berulang dan meningkatkan hasil terapi. Tinjauan literatur ini bertujuan untuk mengeksplorasi tata laksana dislipidemia saat ini di Indonesia dan membahas peran potensial strategi ACS Europath untuk meningkatkan kualitas hidup pasien.
Unduhan
Referensi
Kementerian Kesehatan RI. Dislipidemia. Perpustakaan Kementerian Kesehatan RI [Internet] 2023. Available from: https://perpustakaan.kemkes.go.id/asset_perpustakaan_kemkes/upload/pathfinder/2023/8/Kemenkes-RI-Dislipidemia.pdf.
Aman AM, Soewondo P, Soelistijo SA, Arsana PM, Wismandari, Zufry H, et al. Panduan pengelolaan dislipidemia di Indonesia. PB PERKENI; 2021
Eliyanti U, Hanif I. Hypertension and cholesterol among late adults in Indonesia: A cross-sectional population-based survey. J Health Economic Policy Res (JHEPR). 2023;1(1):31–4. DOI: 10.30595/jhepr.v1i1.70.
Hatma RD. Lipid profiles among diverse ethnic groups in Indonesia. Acta Med Indones. 2011;43(1):4-11. PMID: 21339539.
Lee ZV, Llanes EJ, Sukmawan R, Thongtang N, Ho HQT, Barter P. Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region. Lipids Health Dis. 2021;20(1):33. DOI: 10.1186/s12944-021-01450-8.
Erwinanto, Ng S, Santoso A, Desandri DR, Erika, Sukmawan R, et al. Panduan tatalaksana dislipidemia 2022. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia [Internet]. 2022. Available from: https://www.inaheart.org/storage/guideline/7f75cffa237e402536f3d425012d985d.pdf.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/ EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce car diovascular risk. Eur Heart J 2020;41:111–88. DOI: 10.1093/eurheartj/ehz455.
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:2459–72. DOI: 10.1093/eurheartj/ehx144.
Navarese EP, Kowalewski M, Andreotti F, van Wely M, Camaro C, Kolodziejczak M, et al. Meta-analysis of time-related benefits of statin therapy in patients with acute cor onary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2014;113:1753–64. DOI: 10.1016/j.amjcard.2014.02.034.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97. DOI: 10.1056/NEJMoa1410489.
Catapano AL, De Caterina R, Jukema JW, Klempfner R, Landmesser U, Schiele F, et al. Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative. Clin Cardiol. 2023;46(4):407–15. DOI: 10.1002/clc.23988.
Suastika K, Semadi IMS, Dwipayana IMP, Saraswati MR, Gotera W, Budhiarta AAG, et al. Dyslipidemia in diabetes: A population-based study in Bali. Int J Gen Med. 2019;12:313–21. DOI: 10.2147/ijgm.s215548.
Schiele F, Catapano AL, De Caterina R, Laufs U, Jukema JW, Zaman A, et al. Quality control to improve LDL-cholesterol management in patients with acute coronary syndromes based on the ACS EuroPath IV project. Eur Heart J Acute Cardiovasc Care. 2024;13(1):46–54. DOI: 10.1093/ehjacc/zuad119.
Laufs U, Catapano AL, De Caterina R, Schiele F, Sionis A, Zaman A, et al. The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project. Vascul Pharmacol. 2023;148(107141):107141. DOI: 10.1016/j.vph.2023.107141.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713–22. DOI: 10.1056/NEJMoa1615664.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:2097–117. DOI: 10.1056/NEJMoa1801174.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2025 Richard Antonius
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
